Sunshine Biopharma (SBFM) Common Equity (2010 - 2026)
Sunshine Biopharma's (SBFM) quarterly Common Equity came in at $21.5 million in Q1 2026, down 5.22% YoY from $22.7 million in Q1 2025, and down 6.61% on a QoQ basis from $23.0 million in Q4 2025.
Sunshine Biopharma (SBFM) Common Equity (2010 - 2026) Analysis & Trends
Sunshine Biopharma (SBFM) has 17 years of Common Equity data on file, last reported at $21.5 million in Q1 2026.
- Quarterly Common Equity fell 5.22% year-over-year to $21.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $21.5 million (down 5.22% YoY) and the FY2025 annual result came in at $23.0 million, down 1.97% from the prior year.
- Common Equity slipped to $21.5 million in Q1 2026, from $23.0 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $41.9 million in Q2 2022 to a low of $13.3 million in Q1 2022.
- A 5-year average of $24.5 million and a median of $23.1 million in 2023 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2022 — Common Equity soared 10117.97% — and 2023, when it tumbled 45.61%.
- Tracing SBFM's Common Equity over 5 years: stood at $21.6 million in 2022, then dropped by 1.94% to $21.2 million in 2023, then advanced by 10.81% to $23.5 million in 2024, then retreated by 1.97% to $23.0 million in 2025, then slipped by 6.61% to $21.5 million in 2026.
- The last three Common Equity figures came in at $21.5 million (Q1 2026), $23.0 million (Q4 2025), and $24.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 22.06 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 7.76 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 3.15 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 47.42 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 6.40 Bn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 14.26 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 3.69 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 6.59 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 4.05 Bn |
| 10 | Sunshine Biopharma | 1.58 Mn | -12.17 Mn | 2.43 Mn | 27.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 27.54 Mn |
| Mar 31, 2026 | 21.52 Mn |
| Dec 31, 2025 | 23.04 Mn |
| Sep 30, 2025 | 24.20 Mn |
| Jun 30, 2025 | 25.68 Mn |
| Mar 31, 2025 | 22.70 Mn |
| Dec 31, 2024 | 23.50 Mn |
| Sep 30, 2024 | 25.04 Mn |
| Jun 30, 2024 | 23.49 Mn |
| Mar 31, 2024 | 24.82 Mn |
| Dec 31, 2023 | 21.21 Mn |
| Sep 30, 2023 | 21.96 Mn |
| Jun 30, 2023 | 23.11 Mn |
| Mar 31, 2023 | 19.43 Mn |
| Dec 31, 2022 | 21.63 Mn |
| Sep 30, 2022 | 40.38 Mn |
| Jun 30, 2022 | 41.89 Mn |
| Mar 31, 2022 | 13.31 Mn |
| Dec 31, 2021 | 211,662.00 |
| Sep 30, 2021 | -1.17 Mn |